Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azeflu is a fixed-dose combination nasal spray containing azelastine hydrochloride and fluticasone propionate. It is primarily indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis in patients who require both an antihistamine and a corticosteroid for symptom control. Azelastine is a second-generation H1-receptor antagonist that provides rapid relief of nasal symptoms by blocking histamine H1 receptors and inhibiting the release of inflammatory mediators. Fluticasone propionate is a synthetic corticosteroid that exerts potent anti-inflammatory effects by binding to glucocorticoid receptors, thereby reducing mucosal edema and inflammatory cell infiltration. This combination therapy is designed to provide superior efficacy compared to either component used alone by addressing both the immediate and late-phase allergic responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azelastine + fluticasone propionate.